Long‐term weight control study IV (weeks 156 to 190): The second double‐blind phase

Michael Weintraub, Pavur R. Sundaresan, Barbara Schuster, Mordechai Averbuch, E. Carol Stein, Christopher Cox, Louise Byrne

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

To assess continued efficacy of anorexiants after 3 years of use, 52 participants (43% of those starting) entered a second double‐blind trial to compare 60 mg sustained‐release fenfluramine plus 15 mg phentermine resin versus placebo added to behavior modification, caloric restriction, and exercise. Although participants in both the active medication and placebo groups gained weight, participants receiving fenfluramine plus phentermine (n = 27) gained significantly (p < 0.01) less (4.4 ± 0.5 kg or 5.3% ± 0.5% of initial weight) than participants receiving placebo (n = 24) (6.9 ± 0.8 kg or 8.5% ± 1.1% of initial weight). At week 190, both groups were still below their initial weight (fenfluramine plus phentermine group, 5.0 ± 1.4 kg; placebo group, 2.1 ± 1.2 kg; p < 0.01). Overall, 12 participants (23.5% of those still in the study) were ≥10% below initial weight. One participant dropped out during this phase because of personal reasons and loss of medication efficacy. During the 30 weeks, participants receiving fenfluramine plus phentermine had 26 moderate or severe complaints versus eight participants receiving placebo. Fenfluramine plus phentermine provided better appetite control and only slightly more bother. Analysis of participant response in this phase by treatment assignment in the first double‐blind phase (weeks 6 to 34) indicated that initial receipt of medication did not have negative learning effects. Eleven participants receiving active medication between weeks 6 and 34 and receiving placebo between weeks 160 to 190 gained 5.1 ± 1.0 kg. In contrast, 13 participants originally taking placebo gained 8.3 ± 9 kg in this second double‐blind phase. Participants titrated to higher doses of medication in the period from weeks 104 to 156 had a greater increase in their weights during the second double‐blind study. Clinical Pharmacology and Therapeutics (1992) 51, 608–614; doi:

Original languageEnglish (US)
Pages (from-to)608-614
Number of pages7
JournalClinical Pharmacology & Therapeutics
Volume51
Issue number5
DOIs
StatePublished - May 1992

Fingerprint

Phentermine
Fenfluramine
Placebos
Weights and Measures
Caloric Restriction
Behavior Therapy
Clinical Pharmacology
Appetite
Learning
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Weintraub, M., Sundaresan, P. R., Schuster, B., Averbuch, M., Stein, E. C., Cox, C., & Byrne, L. (1992). Long‐term weight control study IV (weeks 156 to 190): The second double‐blind phase. Clinical Pharmacology & Therapeutics, 51(5), 608-614. https://doi.org/10.1038/clpt.1992.72

Long‐term weight control study IV (weeks 156 to 190) : The second double‐blind phase. / Weintraub, Michael; Sundaresan, Pavur R.; Schuster, Barbara; Averbuch, Mordechai; Stein, E. Carol; Cox, Christopher; Byrne, Louise.

In: Clinical Pharmacology & Therapeutics, Vol. 51, No. 5, 05.1992, p. 608-614.

Research output: Contribution to journalArticle

Weintraub, M, Sundaresan, PR, Schuster, B, Averbuch, M, Stein, EC, Cox, C & Byrne, L 1992, 'Long‐term weight control study IV (weeks 156 to 190): The second double‐blind phase', Clinical Pharmacology & Therapeutics, vol. 51, no. 5, pp. 608-614. https://doi.org/10.1038/clpt.1992.72
Weintraub, Michael ; Sundaresan, Pavur R. ; Schuster, Barbara ; Averbuch, Mordechai ; Stein, E. Carol ; Cox, Christopher ; Byrne, Louise. / Long‐term weight control study IV (weeks 156 to 190) : The second double‐blind phase. In: Clinical Pharmacology & Therapeutics. 1992 ; Vol. 51, No. 5. pp. 608-614.
@article{ccb8231f1c1f4b2bb9ea728367c860c0,
title = "Long‐term weight control study IV (weeks 156 to 190): The second double‐blind phase",
abstract = "To assess continued efficacy of anorexiants after 3 years of use, 52 participants (43{\%} of those starting) entered a second double‐blind trial to compare 60 mg sustained‐release fenfluramine plus 15 mg phentermine resin versus placebo added to behavior modification, caloric restriction, and exercise. Although participants in both the active medication and placebo groups gained weight, participants receiving fenfluramine plus phentermine (n = 27) gained significantly (p < 0.01) less (4.4 ± 0.5 kg or 5.3{\%} ± 0.5{\%} of initial weight) than participants receiving placebo (n = 24) (6.9 ± 0.8 kg or 8.5{\%} ± 1.1{\%} of initial weight). At week 190, both groups were still below their initial weight (fenfluramine plus phentermine group, 5.0 ± 1.4 kg; placebo group, 2.1 ± 1.2 kg; p < 0.01). Overall, 12 participants (23.5{\%} of those still in the study) were ≥10{\%} below initial weight. One participant dropped out during this phase because of personal reasons and loss of medication efficacy. During the 30 weeks, participants receiving fenfluramine plus phentermine had 26 moderate or severe complaints versus eight participants receiving placebo. Fenfluramine plus phentermine provided better appetite control and only slightly more bother. Analysis of participant response in this phase by treatment assignment in the first double‐blind phase (weeks 6 to 34) indicated that initial receipt of medication did not have negative learning effects. Eleven participants receiving active medication between weeks 6 and 34 and receiving placebo between weeks 160 to 190 gained 5.1 ± 1.0 kg. In contrast, 13 participants originally taking placebo gained 8.3 ± 9 kg in this second double‐blind phase. Participants titrated to higher doses of medication in the period from weeks 104 to 156 had a greater increase in their weights during the second double‐blind study. Clinical Pharmacology and Therapeutics (1992) 51, 608–614; doi:",
author = "Michael Weintraub and Sundaresan, {Pavur R.} and Barbara Schuster and Mordechai Averbuch and Stein, {E. Carol} and Christopher Cox and Louise Byrne",
year = "1992",
month = "5",
doi = "10.1038/clpt.1992.72",
language = "English (US)",
volume = "51",
pages = "608--614",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Long‐term weight control study IV (weeks 156 to 190)

T2 - The second double‐blind phase

AU - Weintraub, Michael

AU - Sundaresan, Pavur R.

AU - Schuster, Barbara

AU - Averbuch, Mordechai

AU - Stein, E. Carol

AU - Cox, Christopher

AU - Byrne, Louise

PY - 1992/5

Y1 - 1992/5

N2 - To assess continued efficacy of anorexiants after 3 years of use, 52 participants (43% of those starting) entered a second double‐blind trial to compare 60 mg sustained‐release fenfluramine plus 15 mg phentermine resin versus placebo added to behavior modification, caloric restriction, and exercise. Although participants in both the active medication and placebo groups gained weight, participants receiving fenfluramine plus phentermine (n = 27) gained significantly (p < 0.01) less (4.4 ± 0.5 kg or 5.3% ± 0.5% of initial weight) than participants receiving placebo (n = 24) (6.9 ± 0.8 kg or 8.5% ± 1.1% of initial weight). At week 190, both groups were still below their initial weight (fenfluramine plus phentermine group, 5.0 ± 1.4 kg; placebo group, 2.1 ± 1.2 kg; p < 0.01). Overall, 12 participants (23.5% of those still in the study) were ≥10% below initial weight. One participant dropped out during this phase because of personal reasons and loss of medication efficacy. During the 30 weeks, participants receiving fenfluramine plus phentermine had 26 moderate or severe complaints versus eight participants receiving placebo. Fenfluramine plus phentermine provided better appetite control and only slightly more bother. Analysis of participant response in this phase by treatment assignment in the first double‐blind phase (weeks 6 to 34) indicated that initial receipt of medication did not have negative learning effects. Eleven participants receiving active medication between weeks 6 and 34 and receiving placebo between weeks 160 to 190 gained 5.1 ± 1.0 kg. In contrast, 13 participants originally taking placebo gained 8.3 ± 9 kg in this second double‐blind phase. Participants titrated to higher doses of medication in the period from weeks 104 to 156 had a greater increase in their weights during the second double‐blind study. Clinical Pharmacology and Therapeutics (1992) 51, 608–614; doi:

AB - To assess continued efficacy of anorexiants after 3 years of use, 52 participants (43% of those starting) entered a second double‐blind trial to compare 60 mg sustained‐release fenfluramine plus 15 mg phentermine resin versus placebo added to behavior modification, caloric restriction, and exercise. Although participants in both the active medication and placebo groups gained weight, participants receiving fenfluramine plus phentermine (n = 27) gained significantly (p < 0.01) less (4.4 ± 0.5 kg or 5.3% ± 0.5% of initial weight) than participants receiving placebo (n = 24) (6.9 ± 0.8 kg or 8.5% ± 1.1% of initial weight). At week 190, both groups were still below their initial weight (fenfluramine plus phentermine group, 5.0 ± 1.4 kg; placebo group, 2.1 ± 1.2 kg; p < 0.01). Overall, 12 participants (23.5% of those still in the study) were ≥10% below initial weight. One participant dropped out during this phase because of personal reasons and loss of medication efficacy. During the 30 weeks, participants receiving fenfluramine plus phentermine had 26 moderate or severe complaints versus eight participants receiving placebo. Fenfluramine plus phentermine provided better appetite control and only slightly more bother. Analysis of participant response in this phase by treatment assignment in the first double‐blind phase (weeks 6 to 34) indicated that initial receipt of medication did not have negative learning effects. Eleven participants receiving active medication between weeks 6 and 34 and receiving placebo between weeks 160 to 190 gained 5.1 ± 1.0 kg. In contrast, 13 participants originally taking placebo gained 8.3 ± 9 kg in this second double‐blind phase. Participants titrated to higher doses of medication in the period from weeks 104 to 156 had a greater increase in their weights during the second double‐blind study. Clinical Pharmacology and Therapeutics (1992) 51, 608–614; doi:

UR - http://www.scopus.com/inward/record.url?scp=0026544763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026544763&partnerID=8YFLogxK

U2 - 10.1038/clpt.1992.72

DO - 10.1038/clpt.1992.72

M3 - Article

C2 - 1587075

AN - SCOPUS:0026544763

VL - 51

SP - 608

EP - 614

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -